Stay updated on Fazirsiran in AATD Liver Disease Clinical Trial
Sign up to get notified when there's something new on the Fazirsiran in AATD Liver Disease Clinical Trial page.

Latest updates to the Fazirsiran in AATD Liver Disease Clinical Trial page
- Check7 days agoChange DetectedThe record now describes a completed Phase 2 study of fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease, including its design, outcomes, eligibility criteria, and locations. It also provides posted study results and study documents.SummaryDifference58%

- Check14 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA banner announces NIH website transition updates and says federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI).SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 page.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s revision label changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study details view with an access-denied page and a Home link.SummaryDifference0.5%

Stay in the know with updates to Fazirsiran in AATD Liver Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fazirsiran in AATD Liver Disease Clinical Trial page.